Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 24, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Humana Inc. (NYSE: HUM), Illumina Inc. (NASDAQ: ILMN), Edwards Lifesciences Corp. (NYSE: EW), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and CytRx Corporation (NASDAQ: CYTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Humana Inc. Research Report
On December 16, 2013, Humana Inc. (Humana) announced that Kurt J. Hilzinger, currently serving as Lead Director, will become the Chairman of the Board of the Company after the retirement of Michael B. McCallister, effective December 31, 2013. Humana stated that McCallister has been the Chairman of the Board since his appointment to that position in August 2010. McCallister commented, "Kurt's role as Lead Director has prepared him well to lead Humana's Board of Directors upon my retirement. I have full confidence that he will continue to ensure corporate governance and accountability to our shareholders remain at the forefront for our directors." The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/496b_HUM
--
Illumina Inc. Research Report
On December 19, 2013, Illumina Inc.'s (Illumina) stock declined 1.06%, ending the day at $103.51. Over the previous three trading sessions, shares of Illumina increased 0.89%, compared to the Nasdaq Composite, which advanced 0.71% during the same period. The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/3cf2_ILMN
--
Edwards Lifesciences Corp. Research Report
On December 19, 2013, Edwards Lifesciences Corp.'s (Edwards Lifesciences) stock increased 0.35%, ending the day at $63.97. Over the previous three trading sessions, shares of Edwards Lifesciences increased 1.80%, compared to the Dow Jones Industrial Average, which gained 1.85% during the same period. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/48b8_EW
--
Aegerion Pharmaceuticals, Inc. Research Report
On December 19, 2013, Aegerion Pharmaceuticals, Inc.'s (Aegerion Pharmaceuticals) stock declined 1.02%, ending the day at $64.33. Over the previous three trading sessions, shares of Aegerion Pharmaceuticals declined 2.90%, compared to the Nasdaq Composite, which increased 0.71% during the same period. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/a3f6_AEGR
--
CytRx Corporation Research Report
On December 19, 2013, CytRx Corporation's (CytRx) stock declined 6.15%, ending the day at $4.88. Over the previous three trading sessions, shares of CytRx declined 6.51%, compared to the Nasdaq Composite, which increased 0.71% during the same period. The Full Research Report on CytRx Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/1869_CYTR
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner